EGFR and non-small cell lung carcinoma: Another study addressing EGFR and MET inihibiton was the Phase Ib/II study of capmatinib plus gefitinib, which demonstrated preliminary clinical activity (ORR 47%) in patients with EGFR-mutated NSCLC and MET-amplified tumors after progression on EGFR-TKI therapy10.